Allcells, Llc

CLIA Laboratory Citation Details

4
Total Citations
25
Total Deficiencyies
8
Unique D-Tags
CMS Certification Number 22D2126670
Address 1250 Hancock St, Quincy, MA, 02169
City Quincy
State MA
Zip Code02169
Phone(510) 521-2600

Citation History (4 surveys)

Survey - May 6, 2025

Survey Type: Special

Survey Event ID: QWXX11

Deficiency Tags: D0000 D2016 D2130 D6000 D6016 D0000 D2016 D2130 D6000 D6016

Summary:

Summary Statement of Deficiencies D0000 A CLIA paper desk review of proficiency testing was conducted for the the AllCells, LLC laboratory on 05/06/2025 pursuant to the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and CLIA regulations at 42 CFR 493 and the following Condition level deficiencies were deemed to be not met: D2016 - 42 CFR 493.803 Condition: Proficiency Testing - Successful Participation D6000 - 42 C.F.R. 493.1403 Condition: Laboratories performing moderate complexity testing; laboratory director . D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: . Based on a proficiency testing desk review of the Certification and Survey Provider Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- Enhanced Reporting (CASPER) 0155D report and American Association of Bioanalysts (AAB) Proficiency Testing 2024 (Events 1 and 3) and 2025 (Event 1) records, the laboratory failed to successfully participate in a proficiency testing program approved by HHS, for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. The laboratory failed to achieve satisfactory performance (80% or better) for the same analyte for three out of four consecutive testing events for the hematology Hematocrit (HCT) analyte leading to non-initial unsatisfactory performance. Refer to D2130. . D2130 HEMATOLOGY CFR(s): 493.851(f) (f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: . Based on a proficiency testing desk review of CASPER 0155D report and American Association of Bioanalysts (AAB) Proficiency Testing 2024 (Events 1 and 3) and 2025 (Event 1) records, the laboratory failed to attain an overall testing event score of at least 80 percent for the hematology Hematocrit (HCT) analyte leading to a second unsuccessful performance for the specialty of hematology HCT as evidenced by the following specialty scores obtained. Review of the CASPER 0155D report revealed the following results: Hematology 2024-1st Event the laboratory received an unsatisfactory score of 20% for HCT Hematology 2024-3rd Event the laboratory received an unsatisfactory score of 0% for HCT Hematology 2025-1st Event the laboratory received an unsatisfactory score of 20% for HCT A review of the AAB Proficiency Testing records confirmed the laboratory received the above results. . D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: . Based on a proficiency testing desk review of CASPER 0155D report and American Association of Bioanalysts 2024 and 2025 Proficiency Testing records, the laboratory director failed to provide overall management and direction of the laboratory services. The laboratory director failed to ensure the overall quality of the laboratory services provided. Refer to D6016. . D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: . Based on a proficiency testing desk review of CASPER 0155D report and American -- 2 of 3 -- Association of Bioanalysts 2024 and 2025 Proficiency Testing records, the laboratory director failed to ensure the overall quality of the laboratory services provided. The laboratory director failed to ensure successful participation in an HHS approved proficiency testing program. Refer to D2130. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - December 9, 2024

Survey Type: Special

Survey Event ID: LRCK11

Deficiency Tags: D0000 D2016 D2130 D6000 D6000 D0000 D2016 D2128 D2128 D2130

Summary:

Summary Statement of Deficiencies D0000 A CLIA paper desk review of proficiency testing was conducted for the the AllCells, LLC laboratory on 12/09/2024 pursuant to the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and CLIA regulations at 42 CFR493. Based on evidence of unsuccessful proficiency testing performance for the Hematology Hematocrit analyte, the following Condition level deficiencies were deemed to be not met: D2016 - 42 C.F.R. 493.803 Condition: Successful Participation, Proficiency Testing D6000 - 42 C.F.R. 493.1403 Condition: Laboratories performing moderate complexity testing; laboratory director . D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- . Based on calendar year 2024 proficiency testing review (three testing events) of the American Association of Bioanalysts proficiency testing program the laboratory failed to attain a testing event score of at least 80 percent for the Hematology Hematocrit analyte leading to unsatisfactory performance. The laboratory received an overall testing score for the Hematology Hematocrit analyte of 20 percent for the first testing event of 2024 and a score of 0 percent for the third testing event of 2024. Refer to D2128 and D2130 . D2128 HEMATOLOGY CFR(s): 493.851(e) (1) For any unsatisfactory analyte or test performance or testing event for reasons other than a failure to participate, the laboratory must undertake appropriate training and employ the technical assistance necessary to correct problems associated with a proficiency testing failure. (2) For any unacceptable analyte or testing event score, remedial action must be taken and documented, and the documentation must be maintained by the laboratory for two years from the date of participation in the proficiency testing event. This STANDARD is not met as evidenced by: . Based on calendar year 2024 proficiency testing review (three testing events) of the American Association of Bioanalysts proficiency testing program results, the laboratory failed to undertake remedial action in response to unsatisfactory proficiency testing events as evidenced by the following: The laboratory achieved a Hematocrit analyte score of twenty (20) percent for the first testing event of 2024 and a score of zero (0) for the third testing event of 2024 resulting in an unsatisfactory performance for each of the testing events and overall unsuccessful performance for the analyte (refer to D2130). Based on the second unsatisfactory testing event score there was no assurance that appropriate training had been undertaken, and technical assistance employed, to correct the problems associated with proficiency testing failures. . D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: . Based on calendar year 2024 proficiency testing review (three testing events) of the American Association of Bioanlaysts proficiency testing program results, the laboratory failed to achieve satisfactory performance for the same analyte for two out of three consecutive proficiency testing events as evidenced by the following: The laboratory achieved a Hematocrit analyte score of twenty (20) percent for the first testing event of 2024 and a score of zero (0) for the third testing event of 2024 resulting in an unsatisfactory performance for each of the testing events and overall unsuccessful performance for the analyte. . D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 -- 2 of 3 -- The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: . Based on the deficiencies cited herein, the laboratory director failed to ensure that effective remedial action was instituted in response to unsatisfactory proficiency testing results resulting in the second unsuccessful performance for the Hematocrit analyte in the specialty of Hematology. Refer to D2016, D2128, and D2130. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - June 9, 2022

Survey Type: Standard

Survey Event ID: MOTT11

Deficiency Tags: D0000 D6053

Summary:

Summary Statement of Deficiencies D0000 A CLIA recertification survey was conducted for the AllCells, LLC laboratory pursuant to the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and CLIA regulations at 42 CFR 493. D6053 TECHNICAL CONSULTANT RESPONSIBILITIES CFR(s): 493.1413(b)(9) The technical consultant is responsible for evaluating and documenting the performance of individuals responsible for moderate complexity testing at least semiannually during the first year the individual tests patient specimens. This STANDARD is not met as evidenced by: . Based on personnel competency record review and interview with the Technical Consultant (TC) and Quality Manager on 6/09/2022, the TC failed to evaluate and document the performance of individuals responsible for moderate complexity testing at least semiannually during the first year the individual tested patient specimens as evidenced by the following: The surveyor asked for the personnel competency records for review. The review revealed that semiannual competency evaluations were not performed and documented for seven (7) out of the nine (9) new testing persons (TP) in their first year of performing moderate complexity testing. The TC and Quality Manager confirmed in an interview on 6/09/2022 at 2:05 PM that the TC failed to perform and document semiannual competency evaluations for seven (7) TP's in their first year of performing moderate complexity testing. The laboratory performs 12,000 CBC's annually. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - October 23, 2019

Survey Type: Standard

Survey Event ID: KOTI11

Deficiency Tags: D2005 D2005 D0000

Summary:

Summary Statement of Deficiencies D0000 A CLIA recertification survey was conducted for the AllCells, LLC laboratory pursuant to the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and CLIA regulations at 42 CFR 493. . D2005 ENROLLMENT CFR(s): 493.801(a)(4) Authorize the proficiency testing program to release to HHS all data required to-- (i) Determine the laboratory's compliance with this subpart; and (ii) Make PT results available to the public as required in section 353(f)(3)(F) of the Public Health Service Act. This STANDARD is not met as evidenced by: . Based on record review and interview the laboratory failed to authorize the proficiency testing (PT) program to release all data to Health and Human Services (HHS) as evidenced by the following: A review of the CMS CLIA Application and Summary report revealed no proficiency testing results for Hematology testing. A review of PT records for second and third events in 2018 and calendar year 2019 revealed that the laboratory's CLIA number was not listed on the American Association of Bioanalysts (AAB) PT reports. The technical consultant confirmed through interview at 10:30 AM on 10/23/19 that the AAB PT reports did not contain the laboratory's CLIA number therefore Hematology PT results were not released to HHS. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access